Bilirubin isomers during LED phototherapy of hyperbilirubinemic neonates, blue-green (~478 nm) vs blue
- PMID: 39232092
- DOI: 10.1038/s41390-024-03493-w
Bilirubin isomers during LED phototherapy of hyperbilirubinemic neonates, blue-green (~478 nm) vs blue
Abstract
Background: The clinical part of this randomized controlled trial concerning phototherapy of neonates with hyperbilirubinemia showed that the recommended blue-green LED light (≈478 nm) was 31% more efficient than standard blue LED light (≈459 nm) measured by the decline in total serum bilirubin. Lumirubin has biologic effects. The aim was to compare the serum bilirubin isomers, efficacy, and biologic effects between the two phototherapy groups.
Methods: Inclusion criteria: neonates healthy except for hyperbilirubinemia, gestational age ≥33 weeks, birth weight ≥1800 g, and postnatal age >24 h. Forty-two neonates were randomized to receive overhead blue-green light and 44 blue light. Treatment 24 h. The light irradiance was equal.
Results: The percentage decrease of combined bilirubin isomers was 47.8% for blue-green light vs 33.4% for blue light, the ratio being 1.43. Corresponding values for Z,Z-bilirubin were 55.6% vs 44.2%, the ratio being 1.26. The increase in the absolute serum concentrations of the photoisomer Z,E-bilirubin and thereby combined photoisomers were greater using blue light.
Conclusion: Blue-green light was essentially more efficient determined by the decline of combined bilirubin isomers and Z,Z-bilirubin itself. Regarding biological effects neonates receiving blue-green light might be more affected than neonates receiving blue light.
Impact: Phototherapy of hyperbilirubinemic neonates using blue-green LED light with a peak emission of 478 nm was 43% more efficient than standard blue LED light with a peak emission of 459 nm was measured by the decline of serum combined bilirubin isomers, and the decline of toxic Z,Z-bilirubin was 26% greater. Apparently, there was a discrepancy between the huge drop in total serum bilirubin and the low serum concentrations of E,Z-bilirubin and E,Z-lumirubin. This was caused by the rapid excretion of E,Z-lumirubin. Lumirubin has biologic effects. Due to greater lumirubin production neonates exposed to blue-green light might be more affected than those exposed to blue light.
© 2024. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Conflict of interest statement
Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: Verbal and written informed consent was obtained from the parents. All regulations concerning research, at the time the studies were conducted, were followed. The trial was approved by the Committee for Biomedical Research Ethics in the North Denmark Region, N-20160071, and registered in the Clinical Trial Registry number NCT 03183986.
Similar articles
-
Comparison of BiliCocoon phototherapy with overhead phototherapy in hyperbilirubinemic neonates. A randomized clinical trial.Pediatr Res. 2025 May;97(6):1951-1957. doi: 10.1038/s41390-024-03692-5. Epub 2024 Nov 3. Pediatr Res. 2025. PMID: 39489832 Free PMC article. Clinical Trial.
-
Fluid supplementation for neonatal unconjugated hyperbilirubinaemia.Cochrane Database Syst Rev. 2017 Aug 1;8(8):CD011891. doi: 10.1002/14651858.CD011891.pub2. Cochrane Database Syst Rev. 2017. PMID: 28762235 Free PMC article.
-
Intravenous fluid supplementation in management of severe unconjugated hyperbilirubinemia in preterm neonates-a randomized controlled trial.Eur J Pediatr. 2025 Jun 2;184(6):383. doi: 10.1007/s00431-025-06226-1. Eur J Pediatr. 2025. PMID: 40455331 Clinical Trial.
-
Light-emitting diode phototherapy for unconjugated hyperbilirubinaemia in neonates.Cochrane Database Syst Rev. 2011 Dec 7;2011(12):CD007969. doi: 10.1002/14651858.CD007969.pub2. Cochrane Database Syst Rev. 2011. PMID: 22161417 Free PMC article.
-
Periodic change of body position under phototherapy in term and preterm neonates with hyperbilirubinaemia.Cochrane Database Syst Rev. 2022 Mar 2;3(3):CD011997. doi: 10.1002/14651858.CD011997.pub2. Cochrane Database Syst Rev. 2022. PMID: 35235686 Free PMC article.
References
-
- American Academy of Pediatrics, Kemper et al. Clinical practical guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 150, e2022058959 (2022).
-
- Pichon, J.-B., Riordan, S. M., Watchko, J. & Shapiro, S. The neurological sequelae of hyperbilirubinemia: definitions, diagnosis and treatment of the kernicterus spectrum disorders (KSDs). Curr. Pediatr. Rev. 13, 199–209 (2017). - PubMed
-
- Toenne, A., Meberg, A. & Hager, H. B. Erindring i diagnostik og behandling av hyperbilirubinemi hos nyfødte. Tidskr. Nor. Legeforen 130, 18–24 (2010). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources